Skip to content
drillr.ai

ILMN

Illumina, Inc.

NASDAQ · USHealthcareMedical - Diagnostics & Research
$184.68-1.06%

Price as of Jul 20, 2026

ILMN news

Illumina, Inc. news

A server-rendered, paginated timeline of the latest available company news.

  1. Illumina expands Billion Cell Atlas program with new AI drug developers

    Illumina expands Billion Cell Atlas program with new AI drug developers PR Newswire SAN DIEGO, July 16, 2026 Partners will use unprecedented data scale to advance more precise medicines to approval SAN DIEGO, July 16, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that the Billion Cell Atlas alliance has added three new member companies, including AI-native drug developer Formation Bio. As leaders in AI-driven drug discovery, design, and development, alliance members will

    PR Newswire ·

  2. Illumina to Announce Second Quarter 2026 Financial Results on Thursday, July 30, 2026

    Illumina to Announce Second Quarter 2026 Financial Results on Thursday, July 30, 2026 PR Newswire SAN DIEGO, July 9, 2026 SAN DIEGO, July 9, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) announced today that it will issue results for the second quarter 2026 following the close of market on Thursday, July 30, 2026. On the same day, at 1:30 pm Pacific Time (4:30 pm Eastern Time) Jacob Thaysen, PhD, Chief Executive Officer, and Ankur Dhingra, Chief Financial Officer, will host a conference

    PR Newswire ·

  3. Illumina appoints Michael Sullivan Chief Commercial Officer and Julie Coletti Chief Legal Officer

    Illumina appoints Michael Sullivan Chief Commercial Officer and Julie Coletti Chief Legal Officer PR Newswire SAN DIEGO, July 9, 2026 New leaders bring extensive leadership experience across life sciences, diagnostics, and medical technology SAN DIEGO, July 9, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced the appointment of Mike Sullivan as Chief Commercial Officer, effective July 20, 2026, and Julie Coletti as Chief Legal Officer, effective August 3, 2026. The appointm

    PR Newswire ·

  4. Daniel M. Skovronsky, MD, PhD, appointed to Illumina's Board of Directors

    Daniel M. Skovronsky, MD, PhD, appointed to Illumina's Board of Directors PR Newswire SAN DIEGO, June 23, 2026 Eli Lilly and Company's Chief Scientific and Product Officer brings pharmaceutical R&D and scientific leadership perspective to Illumina's Board SAN DIEGO, June 23, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced the appointment of Daniel M. Skovronsky, MD, PhD, to its Board of Directors, effective June 16, 2026. Dr. Skovronsky brings extensive experience in drug

    PR Newswire ·

  5. IQM Appoints Craig Ciesla, Former Illumina VP, as CTO; Inés de Vega Becomes Chief Scientist

    IQM Appoints Craig Ciesla, Former Illumina VP, as CTO; Inés de Vega Becomes Chief Scientist * Ciesla is a seasoned deep tech executive with more than 25 years of experience delivering products across industries — from startups to Fortune 500 companies. * De Vega brings more than 20 years of experience advancing quantum technologies from fundamental research to intellectual property and industrial applications. IQM Quantum Computers, the global leader in superconducting quantum computers, t

    Business Wire ·

  6. Illumina launches StrataMap Spatial Solution, a powerful end-to-end spatial whole transcriptome research solution

    Illumina launches StrataMap Spatial Solution, a powerful end-to-end spatial whole transcriptome research solution PR Newswire SAN DIEGO, June 8, 2026 StrataMap Spatial gives researchers access to spatial biology at true single cell resolution for discovery without boundaries Whole-transcriptome profiling across a large tissue capture area can generate 2x more unique genes per sample than probe-based technologies SAN DIEGO, June 8, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today ann

    PR Newswire ·

  7. Illumina and SPT Labtech unveil fireflyGO, enabling faster, simpler targeted oncology research

    Illumina and SPT Labtech unveil fireflyGO, enabling faster, simpler targeted oncology research PR Newswire SAN DIEGO, May 28, 2026 Automating library prep reduces hands-on time for customers using Pillar Biosciences oncoReveal® targeted oncology research panels SAN DIEGO, May 28, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) and SPT Labtech today introduced the fireflyGO automation platform, a new benchtop liquid handling and library preparation solution that brings automation, speed, a

    PR Newswire ·

  8. Illumina introduces the first distributed whole-genome sequencing solution for highly sensitive MRD research

    Illumina introduces the first distributed whole-genome sequencing solution for highly sensitive MRD research PR Newswire SAN DIEGO, May 28, 2026 An advanced research workflow for fast, flexible detection of molecular residual disease during and following treatment Solution is the first in a new WGS oncology portfolio, building on Illumina's history of leadership as foundation for MRD market SAN DIEGO, May 28, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced a new complete

    PR Newswire ·

  9. David P. King elected to Illumina's Board of Directors

    David P. King elected to Illumina's Board of Directors PR Newswire SAN DIEGO, May 21, 2026 Former Labcorp Chairman and CEO brings deep healthcare, diagnostics, and clinical expertise to Illumina's Board SAN DIEGO, May 21, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today confirmed the election of David P. King to its Board of Directors, effective immediately following the company's annual meeting of shareholders. Mr. King's election marks an important addition to Illumina's Board as t

    PR Newswire ·

  10. Illumina releases 2025 Corporate Responsibility Report, expanding access to genomics and accelerating global impact

    Illumina releases 2025 Corporate Responsibility Report, expanding access to genomics and accelerating global impact PR Newswire SAN DIEGO, May 19, 2026 SAN DIEGO, May 19, 2026 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN) today published its annual Corporate Responsibility (CR) Report. The report highlights the company's continued progress in expanding equitable access to genomics while delivering measurable impact for patients, communities, and health systems worldwide. It reinforces Illumina

    PR Newswire ·

  11. Illumina Reports Financial Results for First Quarter of Fiscal Year 2026

    Illumina Reports Financial Results for First Quarter of Fiscal Year 2026 PR Newswire SAN DIEGO, April 30, 2026 SAN DIEGO, April 30, 2026 /PRNewswire/ -- Illumina, Inc. (Nasdaq: ILMN) ("Illumina" or the "company") today announced its financial results for the first quarter of fiscal year 2026. First quarter 2026 results: * Revenue of $1.09 billion for Q1 2026, up 4.8% from Q1 2025 (ROW(1) organic revenue growth of 3.5%) * GAAP operating margin of 19.2% and non-GAAP operating margin of 21.9

    PR Newswire ·

  12. DRAGEN v4.5 supports Illumina's new TruPath Genome and 5-base assays, drives insights across germline, oncology, and multiomic workflows

    DRAGEN v4.5 supports Illumina's new TruPath Genome and 5-base assays, drives insights across germline, oncology, and multiomic workflows PR Newswire SAN DIEGO, April 16, 2026 Illumina launches DRAGEN v4.5, unlocking deep biological signals in complex regions and challenging sample types for rare disease, oncology research New pangenome representation, default personalization, and machine learning features boost analytical capabilities across applications SAN DIEGO, April 16, 2026 /PRNewswir

    PR Newswire ·

  13. Illumina and the Center for Data-Driven Discovery in Biomedicine bring genomic data and scalable software to the fight against pediatric cancer and rare disease

    Illumina and the Center for Data-Driven Discovery in Biomedicine bring genomic data and scalable software to the fight against pediatric cancer and rare disease PR Newswire SAN DIEGO, April 14, 2026 Dataset will drive crucial insights to accelerate scientific discovery and ultimately improve pediatric patient care. SAN DIEGO, April 14, 2026 /PRNewswire/ -- Illumina (NASDAQ: ILMN) and the Center for Data-Driven Discovery in Biomedicine (D3b) today announced a data partnership to advance resea

    PR Newswire ·

  14. Illumina to Announce First Quarter 2026 Financial Results on Thursday, April 30, 2026

    Illumina to Announce First Quarter 2026 Financial Results on Thursday, April 30, 2026 PR Newswire SAN DIEGO, April 9, 2026 SAN DIEGO, April 9, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) announced today that it will issue results for the first quarter 2026 following the close of market on Thursday, April 30, 2026. On the same day, at 1:30 pm Pacific Time (4:30 pm Eastern Time) Jacob Thaysen, PhD, Chief Executive Officer, and Ankur Dhingra, Chief Financial Officer, will host a conference ca

    PR Newswire ·

  15. Illumina Announces Changes to Board of Directors

    Illumina Announces Changes to Board of Directors PR Newswire SAN DIEGO, April 2, 2026 David P. King nominated to support next phase of growth and innovation; Frances Arnold, Robert S. Epstein, and Gary S. Guthart to retire from the Board SAN DIEGO, April 2, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced changes to its Board of Directors. Frances Arnold, PhD, Robert S. Epstein, MD, and Gary S. Guthart, PhD, will retire from the Board in connection with the company's upcoming a

    PR Newswire ·

  16. Illumina and Labcorp expand collaboration to broaden access to precision oncology testing

    Illumina and Labcorp expand collaboration to broaden access to precision oncology testing PR Newswire SAN DIEGO, March 18, 2026 SAN DIEGO, March 18, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) and Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced an expanded collaboration to advance precision oncology through innovative applications of next-generation sequencing (NGS) solutions across the healthcare ecosystem. Projects are expected to

    PR Newswire ·

  17. Illumina advances preventive genomics through strategic consortium with Veritas Genetics

    Illumina advances preventive genomics through strategic consortium with Veritas Genetics PR Newswire SAN DIEGO, March 16, 2026 New collaboration aims to bring population-scale whole-genome sequencing into everyday healthcare, enabling earlier risk detection and data-driven prevention SAN DIEGO, March 16, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced a strategic collaboration with Veritas Genetics Powered By Fuze Health to form a consortium that aims to bring preventive genom

    PR Newswire ·

  18. Alliance for Genomic Discovery expands with Regeneron Genetics Center membership and new proteomics data offering

    Alliance for Genomic Discovery expands with Regeneron Genetics Center membership and new proteomics data offering PR Newswire SAN DIEGO, March 5, 2026 Dataset grows to more than 312,000 whole genomes with longitudinal clinical data GSK is one of the first to lead a further expansion of 50,000 whole genomes paired with proteomic data SAN DIEGO, March 5, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), and Nashville Biosciences, LLC (NashBio), today announced two advancements in scale and depth

    PR Newswire ·

  19. Illumina whole-genome sequencing technology to accelerate rare disease testing in Florida

    Illumina whole-genome sequencing technology to accelerate rare disease testing in Florida PR Newswire SAN DIEGO, Feb. 27, 2026 Increased adoption of clinical whole-genome sequencing is advancing diagnostics for rare diseases, which affect 15 million American children SAN DIEGO, Feb. 27, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that Illumina Laboratory Services, Illumina's CLIA-certified laboratory, is providing clinical sequencing and interpretation services to the new

    PR Newswire ·

  20. Illumina Launches TruPath Genome, Unveils NovaSeq X Roadmap, and Drives Cancer Breakthroughs with Connected Multiomics

    For best results when printing this announcement, please click on link below: https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260227:nPNA1Y7sNa&default-theme=true Illumina Launches TruPath Genome, Unveils NovaSeq X Roadmap, and Drives Cancer Breakthroughs with Connected Multiomics PR Newswire SAN DIEGO, Feb. 27, 2026 * TruPath™ Genome offers more complete genome, with the simplest sample to sequencer workflow, and the new AGBT data demonstrates its accuracy in d

    PR Newswire ·